Opinion|Videos|August 2, 2024
Sequencing Second-Line Treatments for LR-MDS
Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.
Advertisement
Episodes in this series
- Let’s explore sequencing strategies for lower-risk MDS in the 2L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Komrokji: How do you approach treating patients with luspatercept from based on data from the MEDALIST trial? (
Santini V, et al. ASH 2023. Abstract 915 )- What is the impact of fatigue events on overall treatment outcomes in patients treated with luspatercept for LR-MDS?
- Dr. Thomas Cluzeau: Based on the results from the MEDALIST trial, how would you approach dose escalation for 2L treatment of luspatercept in patients with LR-MDS? (
Platzbecker U et al. Blood 2022 )
Advertisement
Related to this article
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
5